Table 2. Pooled-analysis results of the percentage change in level of serum lipid and the incidence of adverse events.
| Outcomes | Patients, n | WMD/RR (95% CI) | P value | I2, % | Heterogeneity P value |
|---|---|---|---|---|---|
| LDL-C | 1875 | −48.54 %[-53.19, -43.88] | P < 0.00001 | 100% | P < 0.00001 |
| HDL-C | 1460 | 6.29 %[5.12, 7.46] | P < 0.00001 | 97% | P < 0.00001 |
| TC | 1082 | −31.08%[-35.20, -26.95] | P < 0.00001 | 99% | P < 0.00001 |
| Lp(a) | 1383 | −20.44%[-25.21, -15.66] | P < 0.00001 | 100% | P < 0.00001 |
| ApoA1 | 1392 | 4.86%[3.77, 5.95] | P < 0.00001 | 97% | P < 0.00001 |
| ApoB | 1438 | −36.32%[-40.75, -31.90] | P < 0.00001 | 100% | P < 0.00001 |
| TG | 1383 | −7.92%[-19.19, 3.36] | P = 0.17 | 100% | P < 0.00001 |
| Adverse events | 1462 | 1.03[0.92, 1.15] | P = 0.64 | 40% | P = 0.13 |
| Serious adverse events | 1385 | 1.05[0.70, 1.58] | P = 0.80 | 0% | P = 0.69 |
| Discontinuation | 545 | 1.01[0.09, 10.89] | P = 0.99 | NA | NA |
| Death | 545 | NE | NA | NA | NA |
| Headache | 1301 | 0.83[0.49, 1.38] | P = 0.46 | 0% | P = 0.86 |
| Injection site reactions | 1421 | 1.43[0.93, 2.21] | P = 0.10 | 0% | P = 0.66 |
| Nasopharyngitis | 1385 | 1.09[0.78, 1.54] | P = 0.61 | 31% | P = 0.20 |
| Gastroenteritis | 571 | 1.15[0.49, 2.66] | P = 0.75 | 31% | P = 0.22 |
| Nausea | 652 | 0.67[0.28, 1.62] | P = 0.37 | 47% | P = 0.13 |
| Upper respiratory tract infections | 701 | 1.03[0.53, 1.99] | P = 0.93 | 0% | P = 0.37 |
| AST or ALT>3ULN | 622 | 1.49[0.24, 9.10] | P = 0.67 | 0% | P = 0.62 |
| CK>5ULN | 622 | 0.63[0.17, 2.29] | P = 0.48 | 28% | P = 0.25 |
WMD, weighted mean difference; RR, risk ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; Lp(a), lipoprotein(a); ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; TG, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase; ULN, upper limit of normal; NA, not applicable; NE, not estimable.